Summit Therapeutics Inc. (NASDAQ:SMMT) partner Akeso Inc. on Wednesday released positive topline findings from its randomized Phase 3 HARMONi-GI1 clinical trial (or AK112-309).
The study evaluated ivonescimab paired with chemotherapy against durvalumab combined with chemotherapy as a first-line therapy for patients diagnosed with advanced biliary tract cancer.
Ivonescimab Demonstrates Superior Survival Endpoint
A pre-specified interim analysis revealed that the ivonescimab combination achieved statistically significant and clinically meaningful superiority in overall survival over the durvalumab combination.
This primary endpoint result highlights a notable outcome, as durvalumab combined with chemotherapy is currently the preferred first-line immunotherapy regimen recommended by international medical guidelines and recognized as the optimal standard of care.
